Inflammation and Lung Cancer (PDF)

Name: Inflammation and Lung Cancer
Brand: Springer-Verlag GmbH
SKU: 69907178
Price: 96.29 EUR
Availability: OnlineOnly

(Sprache: Englisch)

Schreiben Sie einen Kommentar zu "Inflammation and Lung Cancer".

Merken

¿¿¿¿¿¿¿¿¿¿

This volume presents aspects of the inflammatory tumor microenvironment (TME) and its many roles in tumor progression and metastasis, including creation of a hypoxic environment, increased angiogenesis and invasion, changes in...

Mehr zum Inhalt Autorenporträt Video

eBook (pdf) 96.29 €

Buch (Gebunden) 106.99 €

sofort als Download lieferbar

Bestellnummer: 69907178

Printausgabe 106.99 €

eBook (pdf) -10% 96.29 €

Download bestellen

Verschenken

48 DeutschlandCard Punkte sammeln

Lastschrift, Kreditkarte, Paypal, Rechnung
Kostenloser tolino webreader

Produktdetails

Produktbeschreibung
Autorenporträt
eBook Hilfe
Biblio. Angaben / Produktdetails

Produktinformationen zu „Inflammation and Lung Cancer (PDF)“

¿¿¿¿¿¿¿¿¿¿

This volume presents aspects of the inflammatory tumor microenvironment (TME) and its many roles in tumor progression and metastasis, including creation of a hypoxic environment, increased angiogenesis and invasion, changes in expression of microRNAs (miRNAs), and an increase in a stem cell phenotype. The volume also covers the mechanisms of inflammatory mediators. Chronic overexpression of inflammatory mediators in the TME, as seen in smokers and patients with non-small cell lung cancer (NSCLC), can also lead to increased tumor initiation, progression, invasion, and metastasis. The volume will provide a comprehensive perspective of the latest findings and summaries of progress made regarding inflammation and its connection to lung cancer.

Autoren-Porträt

Steven M. Dubinett is Professor of Medicine and Pathology at the David Geffen School of Medicine at UCLA, Senior Associate Dean for Translational Research at UCLA, as well as the Director of the UCLA Lung Cancer Research Program. Building on original discoveries relevant to inflammation in the pathogenesis of lung cancer, he has developed a translational research program which now utilizes these laboratory-based discoveries in the translational research. Dr. Dubinett has received continuous peer-reviewed federal funding for translational lung cancer research for more than 20 years.